FDA Grants Faster Approval Pathway for Neurizon Therapeutics' ALS Drug NUZ-001

Neurizon Therapeutics has completed enrollment for its pivotal trial of NUZ-001, a drug for Amyotrophic Lateral Sclerosis (ALS), ahead of schedule. The U.S. Food and Drug Administration has indicated that a single positive study could be sufficient to support the approval of NUZ-001, potentially accelerating its availability for patients with this severe neurodegenerative disease.